| Autor: |
Spronck EA; Department of Research and Development, uniQure biopharma B.V., Amsterdam, the Netherlands., Brouwers CC; Department of Research and Development, uniQure biopharma B.V., Amsterdam, the Netherlands., Vallès A; Department of Research and Development, uniQure biopharma B.V., Amsterdam, the Netherlands., de Haan M; Department of Research and Development, uniQure biopharma B.V., Amsterdam, the Netherlands., Petry H; Department of Research and Development, uniQure biopharma B.V., Amsterdam, the Netherlands., van Deventer SJ; Department of Research and Development, uniQure biopharma B.V., Amsterdam, the Netherlands.; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands., Konstantinova P; Department of Research and Development, uniQure biopharma B.V., Amsterdam, the Netherlands., Evers MM; Department of Research and Development, uniQure biopharma B.V., Amsterdam, the Netherlands. |
| Abstrakt: |
Huntington disease (HD) is a fatal neurodegenerative disorder caused by an autosomal dominant CAG repeat expansion in the huntingtin ( HTT ) gene. The translated expanded polyglutamine repeat in the HTT protein is known to cause toxic gain of function. We showed previously that strong HTT lowering prevented neuronal dysfunction in HD rodents and minipigs after single intracranial injection of adeno-associated viral vector serotype 5 expressing a microRNA targeting human HTT (AAV5-miHTT). To evaluate long-term efficacy, AAV5-miHTT was injected into the striatum of knockin Q175 HD mice, and the mice were sacrificed 12 months post-injection. AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with subsequent suppression of mutant HTT aggregate formation in the striatum and cortex. Functional proof of concept was shown in transgenic R6/2 HD mice. Eight weeks after AAV5-miHTT treatment, a significant improvement in motor coordination on the rotarod was observed. Survival analysis showed that a single AAV5-miHTT treatment resulted in a significant 4-week increase in median survival compared with vehicle-treated R6/2 HD mice. The combination of long-term HTT lowering, reduction in aggregation, prevention of neuronal dysfunction, alleviation of HD-like symptoms, and beneficial survival observed in HD rodents treated with AAV5-miHTT supports the continued development of HTT-lowering gene therapies for HD. |
